Des agents de lutte contre Ebola en Ituri lors de l’épidémie de maladie à virus Bundibugyo en juillet 2026.Crédit : Shevin Jacobs Read in English La première évaluation contrôlée d’un antiviral oral utilisé en prophylaxie post-exposition contre la maladie à virus Ebola pourrait transformer la lutte contre les épidémies.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Gary Kobinger
Protecting those who protect us: the ethics of Ebola post-exposure trials
Ebola response workers in Ituri during the Bundibugyo virus disease outbreak in July 2026.Credit: Shevin Jacobs Lire en français The first controlled evaluation of an oral antiviral as post-exposure prophylaxis for Ebola disease could transform outbreak control. The EBO-PEP trial, now recruiting during the Bundibugyo virus disease outbreak in the Democratic Republic of the Congo (DRC) and Uganda, will determine whether obeldesivir can prevent disease after high-risk exposure.
L’aide publique pour le développement international est une question de sécurité mondiale
Le financement de l’aide publique pour le développement international (APD) est en crise avec une réduction draconienne des sommes allouées par les pays riches aux pays en développement. L’APD existe pour réduire la pauvreté, améliorer l’éducation, la santé et les infrastructures et répondre aux crises humanitaires, et n’inclut pas les dépenses militaires.
Medically Significant Vector-Borne Viral Diseases in Iran
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Plant-made vaccines and therapeutics
Therapeutic proteins such as vaccines, antibodies, hormones, and cytokines are generally produced in bacteria or eukaryotic systems, including chicken eggs and mammalian or insect cell cultures, with high production yield according to well-defined regulatory guidelines (1). The use of plants for the production of therapeutic proteins, called molecular farming, was proposed as an alternative biomanufacturing method in 1986.
Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New DC-Targeting Vaccine Approach Against HIV-1
Vaccines and Antiviral Agents Zhujun Ao, Lijun Wang, Hiva Azizi, Titus Olukitibi Abiola, Gary Kobinger, Xiaojian Yao DOI: 10.1128/JVI.02368-20 ABSTRACT The development of efficient vaccine approaches against HIV infection remains challenging in the vaccine field.
Forewarned, forearmed: to be prepared is half the victory against the next pandemic
Home Page News Opinion Foreign Policy Politics Policy Legislation Lobbying Hill Life & People Hill Climbers Heard On The Hill Calendar Archives Classifieds Hill Times Events Inside Ottawa Directory Hill Times Store Hill Times Careers The Wire Report The Lobby Monitor Parliament Now Subscribe Free Trial Reuse & Permissions Advertising FAQ Log In forewarned-forearmed-to-be-prepared-is-half-the-victory-against-the-next-pandemicAno By Independent Senator Rosa Galvez, Gary Kobinger, and Jacques...
Vaccine innovation spurred by the long wait for an Ebola virus vaccine
The 2013–16 Ebola virus outbreak—the largest ever recorded—substantially hastened the development of an Ebola virus vaccine. Before this outbreak, the safety and immunogenicity of only two Ebola virus vaccine candidates (a DNA-based vaccine and a recombinant adenovirus [rAd] serotype 5-based vaccine) had been evaluated in phase 1 clinical trials.
Pre-existing immunity against Ad vectors
1. Amanna IJ, Messaoudi I, Slifka MK. Protective immunity following vaccination: how is it defined? Hum Vaccin 2008; 4:316-9; PMID:18398296; http://dx.doi.org/10.4161/hv.4.4.5751 [PMC free article] [PubMed] [CrossRef] [Google Scholar] 2. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42; PMID:2230231; http://dx.doi.org/10.1093/infdis/162.5.1036 [PubMed] [CrossRef] [Google Scholar] 3.
Safety and immunogenicity of vesicular stomatitis virus-based vaccines for Ebola virus disease
1 Henao-Restrepo AM Camacho A Longini IM et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017; 389 : 505-518 Although the ability of Ervebo to rapidly mount an immune response in vaccinated individuals has been thoroughly documented, so too have the side-effects associated with such a potent vaccine.
Increased mortality in survivors of Ebola virus disease
Long-term sequelae of Ebola virus disease—including myalgia, arthralgia, ocular diseases, and mental confusion—have come to light in survivors of the 2014–16 Ebola outbreak in west Africa. The frequency and duration of these sequelae, which are collectively referred to as post-Ebola virus disease syndrome, have since been reported. However, information about subsequent mortality in survivors of Ebola is scarce. Anecdotal reports and one previous study 2 Bower H Smout E Bangura MS et al.
Ebola virus is unlikely to become endemic in West Africa
Concern over Ebola becoming endemic in West Africa has appeared in the medical and lay media. Routes of transmission, rates of viral evolution, suitability of humans as hosts and rarity of spillover events make this very unlikely. Without evidence that endemic Ebola is likely, ending epidemics should remain the focus. References 1. MacDougall, C. Liberia Reports New Cases of Ebola. New York Times (2 July 2015); http://go.nature.com/udPXqC 2. WHO Ebola Response Team N. Engl. J. Med. 371, 1481–1495 (2014). 3.
Baited vaccines: A strategy to mitigate rodent‐borne viral zoonoses in humans
Rodents serve as the natural reservoir and vector for a variety of pathogens, some of which are responsible for severe and life‐threatening disease in humans. Despite the significant impact in humans many of these viruses, including Old and New World hantaviruses as well as Arenaviruses, most have no specific vaccine or therapeutic to treat or prevent human infection.
Viral pathogenesis: Unlocking Ebola persistence
The 2013–2016 West African Ebola virus outbreak evidenced that the virus can persist in survivors long-term, leading to sequelae and risks of new transmission chains. Ebola virus has now been shown to behave similarly in rhesus macaques, enabling their use to study persistence and intervention strategies. From its initial discovery in the Democratic Republic of the Congo in 1976 until 2013, Ebola virus (EBOV) disease (EVD) was considered a neglected tropical infection of low public health impact.
How to turn competitors into collaborators
The Ebola epidemic that began December 2013 in a remote Guinean village spread across nations and lasted into 2015, killing 11,000 people and devastating West Africa. Also in 2015, the virus that causes Middle East respiratory syndrome (MERS) broke out in South Korea, only three years after its discovery in Saudi Arabia, thousands of kilometres away.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Gary
Contact Gary, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack